News

BL-5010 is a novel product for the non-surgical removal of benign skin lesions. It offers an alternative to painful, invasive and expensive removal treatments including cryotherapy, laser treatment

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous

The trial will evaluate the safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) with a recent acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).

The randomized, double-blinded, dose-ranging, placebo-controlled Phase 2 trial will evaluate the safety and efficacy of a single, bilateral application of RT001 topical gel for the treatment of primary

US-based New Science Ventures led the financing round, which also included Belgian investors VIVES Louvain Technology Fund, NivelInvest, Fund+, Integrale, SRIW, SFPI-FPIM, Epimède and other individual participants. The

The company’s EySite-NanoM is a sustained-release delivery system designed to offer continuous release of its therapeutic anti-glaucoma agent for preventing the peak and trough drug levels that take

Daratumumab is an investigational, human anti-CD38 monoclonal antibody, which is designed to treat patients with relapsed and refractory multiple myeloma. Multiple myeloma is an incurable blood cancer that

The partnership harnesses Certara’s unmatched biosimulation (modeling and simulation) and regulatory writing capabilities, with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges

The proceeds will be used to advance the company’s ongoing spinal muscular atrophy (SMA) clinical program and expand key operational capabilities. The Class D financing was led by